Gaëtan Devos

MD, PhD - Urology resident @UZLeuven @azsintjanbrugge #ProstateCancer

[Gaëtan Devos @devos_gaetan]

Very proud to present the ARNEO study published in @EUplatinum!!

In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in significantly improved pathological response compared to degarelix alone!
@joniau

A thread🧵👇:
https://t.co/6JG17AiV5u

[steven joniau @joniau]

@jryckman3 @ASTRO_org @urotoday ADT in both arms was deliberate: isolates apalutamide's contribution AND enables the pathological co-primary endpoint (pCR/MRD) — impossible in a surgery-alone design. Deep pathological response predicts BCR-FS and MFS. A scientific necessity, not a flaw. @devos_gaetan @TheGiesen

[Dries Develtere @DriesDeveltere]

Pleased to share that our editorial has been published in European Urology Oncology. We reviewed the randomized evidence on metformin in prostate cancer and found no consistent improvement in meaningful oncologic outcomes across disease stages. The recent SAKK 08/14 trial highlights how future progress may depend less on empirical drug repurposing and more on biomarker-driven strategies, with PTEN as a potential lead. @devos_gaetan @EurUrolOncol
https://t.co/uiWWWoprMz

[European Urology @EUplatinum]

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer by Gaëtan Devos et al

Full article: https://t.co/SEksVXocqP

[Sabine D. Brookman-May @brookmans76]

Congratulations again to #ARNEO study @devos_gaetan @joniau @TheGiesen
▶️MRD doesn't predict BCR
▶️We will need to wait for a possible significant impact on MFS with longer FU
▶️ypT stage correlates with outcomes
👉 Did downstaging after neoadjuvant treatment correlate with BCR?

[Gaëtan Devos @devos_gaetan]

Today we presented the 3 year oncological outcomes of the ARNEO trial:
- Patients treated with 3 mo neoadjuvant ADT + Apalutamide have tendency towards improved BCR free and metastasis free survival.
- pT2 disease associated with less biochemical recurrence.
@joniau @TheGiesen

[UroToday.com @urotoday]

Three-year oncological outcomes of the randomized phase II trial #ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for HR #ProstateCancer. Presented by @devos_gaetan @UZLeuven. #EAU24 written coverage > https://t.co/vEATSLrM7G @RKSayyid

[Thomas Gevaert @GevaertThomas]

Één van mijn mentoren @joniau

Erg toffe mens, uitstekende wetenschapper en dito chirurg.

Veel van geleerd en nog veel van aan het leren 🙂

https://t.co/mwTBOTibPK

[BVU @BVUrologie]

The last day of the #BAU2023 congress is being kicked off with an interesting #ProstateCancer case, presented by @devos_gaetan and moderated by @joniau @vandamme_jvd! Please find the programme on our website 👇 @sb_uro @Uroweb @esru_be https://t.co/2vXhD1Fhj2

[Gaëtan Devos @devos_gaetan]

Nice work by @KarelDavid_ !
Three months of neoadjuvant ADT in high-risk PCa patients results in early bone loss. These findings underscore the importance for bone health prevention in men treated with ADT . @Uroweb @UZLeuven

[Karel David @KarelDavid_]

Happy to see our work highlighted during this #Movember month! Don't forget the impact of #androgendeprivation on #bone in #prostatecancer patients! https://t.co/lKB90ONuv1
Great collaboration with our urology department @devos_gaetan @WoutDevlies @joniau
👇👇👇

[Sabine D. Brookman-May @brookmans76]

Great presentation of #ARNEO results by @joniau #UroOnco23 Neoadjuvant treatment apa/ADT vs ADT prior to RP in #prostatecancer: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR

[Gaëtan Devos @devos_gaetan]

@ESSEVEELIVE Triestig!

[Uros Milenkovic @Uros_ML]

Proud to present our article in @EurUrolOncol: Predictors of recurrence after MDT in oligometastatic prostateCa. Free version below. https://t.co/bGkXJe5s79
Thanks to @joniau @GertMeerleer @CharlienBerghen @J_Kuijk @Eduardrssl @devos_gaetan @VdBroeckThomas @ThomasVdB9

[Dept of Development and Regeneration - KU Leuven @DevReg_KULeuven]

Congratulations to @devos_gaetan for defending his PhD last week🎓👏!

[steven joniau @joniau]

Very proud promotor of @devos_gaetan, who defended his PhD last Friday. Great conclusions and a new adagio: “Eat, sleep, MDT, repeat”. Co-promotors @GertMeerleer & @EveraertsW. Jury @Albert0Briganti, @BertrandTOMBAL, @PieterUvin, prof Claessens and prof Dumez

[Gert De Meerleer @GertMeerleer]

Excellent PhD defense by Gaetan Devos. New treatment options in high-risk prostate cancer and a new proof of the power of metastatis-directed therapy in oligometastatic prostate cancer. Proud to be copromotor 🙏 #respect #prostate #cancer #SBRT #oligo ⁦@joniau⁩ ⁦

[Gert De Meerleer @GertMeerleer]

Excellent dinner after impressive PhD thesis by Gaetan Devos. High-risk prostate cancer and clear evidence in metastasis-directed therapy. Happy to be part of this team. #respect #prostatecancer #SBRT #arneo #oligo ⁦@joniau⁩ ⁦@heinvanpoppel⁩ ⁦@BertrandTOMBAL⁩

[Pieter Uvin @PieterUvin]

Impressive PhD defense yesterday from @devos_gaetan exploring high-risk and oligometastatic prostate cancer, with rightly proud promotors @joniau @EveraertsW @GertMeerleer. Great honour to be in the jury with @Albert0Briganti, @BertrandTOMBAL, Prof Claessens and Prof Durmez.

[Andries Clinckaert @andries_c]

💥 Congratulations to dr. @devos_gaetan for completing his PhD. with an excellent public defense @KU_Leuven

[EAU Edu Platform UROONCO @EAU_Uroonco]

Neoadjuvant degarelix plus apalutamide results ina more favorable pathological outcome when compared with degarelix alone before #radicalprostatectomy.

Read more 👇
https://t.co/pvsoaNynjw

@devos_gaetan @joniau @yraskin @HendrikPoppel @GertMeerleer @roodvdb

#prostatecancer

[Thomas Gevaert @GevaertThomas]

Great achievement by @devos_gaetan and the entire @joniau led @KU_Leuven group, this paper in @EUplatinum

Looking forward to the follow-up projects 💥

https://t.co/RGroTNGGiQ

[Ignacio Rguez. Gomez @urogomez_]

Great job¡¡¡ Congrats to the UH Leuven...steps to a new therapeutic scenario in HR PCa...@joniau @devos_gaetan @GertMeerleer @EveraertsW @heinvanpoppel Lorenzo Tosco,Carl Van Haute et al